Jones v. Merck Sharp & Dohme Corp. et al

Filing 9

ORDER DISMISSING CASE. Signed by Judge Anthony J. Battaglia on 8/12/2022.(exs)

1
2
3
4
5
6
7
8

UNITED STATES DISTRICT COURT

9

SOUTHERN DISTRICT OF CALIFORNIA

10
11
12
13

IN RE INCRETIN-BASED
THERAPIES PRODUCTS LIABILITY
LITIGATION

MDL Case No.: 13-md-2452-AJB-MDD
ORDER GRANTING JOINT
MOTION DISMISSING ALL
REMAINING CASES EXCEPT FOR
THOSE WITH PRO SE PLAINTIFFS

As to All Related and Member Cases

14

(Doc. No. 6494)

15
16

Pursuant to the Joint Motion filed by behalf Plaintiffs’ Steering Committee and

17

Defendants Amylin Pharmaceuticals, LLC, Eli Lilly and Company, Merck Sharp & Dohme

18

Corp (now known as Merck Sharp and Cohme LLC), and Novo Nordisk, Inc., the Court

19

ORDERS that all remaining cases in the MDL are dismissed, except for the following

20

cases with pro se plaintiffs:

21

• Haugabook, L’Queniia, Individually and as the Successor-in-Interest of the Estate

22

of L’Malika Rolling, deceased v. Merck Sharp & Dohme Corp. et al., Case No.

23

3:13-cv-00977-AJB-MDD.

24

• Kovelman, Joyce, Individually and as Successor-in-Interest of the Estate of Gilbert

25

Kovelman, deceased v. Merck Sharp & Dohme Corp. et al., Case No.

26

3:12-cv-03079-AJB-MDD.

27
28

• Foye, Pears and Sharon v. Amylin Pharmaceuticals, LLC et al., Case No.
3:14-cv-00559-AJB-MDD.
1
1

1

Accordingly, the parties’ Joint Motion is GRANTED. (Doc. No. 6494.) The Clerk

2

of Court is instructed to enter this Order in the MDL case and in each corresponding

3

individual case, as well as terminate all other pending motions for voluntary dismissal as

4

moot.

5
6

IT IS SO ORDERED.
Dated: August 12, 2022

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
2
1